Phase 3 data presented at ats 2021 show regen-cov™ (casirivimab with imdevimab) reduced risk of hospitalization or death by 70% in non-hospitalized covid-19 patients

Tarrytown, n.y., may 17, 2021 /prnewswire/ --  patients treated with regen-cov had 4-day shorter duration of symptoms and significantly reduced viral load compared to placebo similar efficacy observed with both doses (1,200 mg and 2,400 mg); u.s. fda is currently reviewing request to add lower 1,200 mg dose to eua regeneron pharmaceuticals, inc. (nasdaq: regn) today announced the presentation of detailed results from the phase 3 pivotal trial showing regen–cov™ (casirivimab with imdevimab) significantly reduced the risk of hospitalization or death, shortened symptom duration and reduced viral load in non-hospitalized patients (outpatients) with covid-19.
REGN Ratings Summary
REGN Quant Ranking